ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: yesterday, 4:59AM

190.86

-0.22 (-0.12%)

  • 1D -0.12%
  • 5D 0.90%
  • 1M 2.77%
  • 6M 10.31%
  • YTD 6.36%
  • 1Y 11.38%
  • 5Y 98.34%
Previous Close 191.08
Open 190.90
Volume 4,191,502
Avg. Volume (3M) 7,707,139
Market Cap 337,135,108,096
Price / Earnings (TTM) 81.22
Price / Earnings (Forward) 15.85
Price / Sales 5.95
Price / Book 239.36
52 Weeks Range
163.52 (-14%) — 218.66 (14%)
Earnings Date 23 Jul 2025 - 28 Jul 2025
TTM Dividend Yield 3.34%
Profit Margin 7.31%
Operating Margin (TTM) 30.43%
Diluted EPS (TTM) 2.35
Quarterly Revenue Growth (YOY) 8.40%
Quarterly Earnings Growth (YOY) -6.10%
Total Debt/Equity (MRQ) 4,789.60%
Current Ratio (MRQ) 0.760
Operating Cash Flow (TTM) 16.40 B
Levered Free Cash Flow (TTM) 16.94 B
Return on Assets (TTM) 8.34%
Return on Equity (TTM) 88.40%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Mixed
Drug Manufacturers - General (Global) Bearish Mixed
Stock AbbVie Inc. Bearish Bullish

AIStockmoo Score

2.1
Analyst Consensus 1.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 1.5
Technical Oscillators 4.0
Average 2.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABBV 337 B 3.34% 81.22 239.36
JNJ 367 B 2.44% 16.95 4.84
PFE 136 B 5.29% 17.39 1.54
BMY 102 B 3.62% 18.44 5.73
GSK 84 B 2.77% 20.16 4.48
LLY 691 B 0.53% 62.09 45.06

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 74.48%
52 Weeks Range
163.52 (-14%) — 218.66 (14%)
Price Target Range
194.00 (1%) — 250.00 (30%)
High 250.00 (Morgan Stanley, 30.99%) Buy
Median 207.50 (8.72%)
Low 194.00 (Goldman Sachs, 1.65%) Hold
Average 213.33 (11.77%)
Total 4 Buy, 2 Hold
Avg. Price @ Call 184.18
Firm Date Target Price Call Price @ Call
Citigroup 14 May 2025 205.00 (7.41%) Hold 177.44
Guggenheim 29 Apr 2025 216.00 (13.17%) Buy 193.51
17 Apr 2025 214.00 (12.12%) Buy 172.99
Evercore ISI Group 28 Apr 2025 205.00 (7.41%) Buy 192.34
Morgan Stanley 28 Apr 2025 250.00 (30.99%) Buy 192.34
09 Apr 2025 241.00 (26.27%) Buy 179.84
Cantor Fitzgerald 22 Apr 2025 210.00 (10.03%) Buy 173.78
Goldman Sachs 08 Apr 2025 194.00 (1.65%) Hold 175.67

No data within this time range.

  • 3M
Date Type Details
17 Jun 2025 CNBC Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
16 Jun 2025 Announcement AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
11 Jun 2025 Announcement U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
03 Jun 2025 Announcement AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
03 Jun 2025 Announcement AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
30 May 2025 Announcement AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
14 May 2025 Announcement AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
14 May 2025 Announcement U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
06 May 2025 Announcement AbbVie to Present at the Bank of America Securities Healthcare Conference
05 May 2025 CNBC Trump signs order to boost domestic drug manufacturing as pharma tariffs loom
01 May 2025 Announcement BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
29 Apr 2025 Announcement RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
25 Apr 2025 Announcement AbbVie Reports First-Quarter 2025 Financial Results
24 Apr 2025 Announcement AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
08 Apr 2025 Announcement AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
31 Mar 2025 Announcement AbbVie to Host First-Quarter 2025 Earnings Conference Call
26 Mar 2025 Announcement AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
24 Mar 2025 Announcement Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
Show more
TTM Dividend Yield 3.34%
5Y Average Dividend Yield 3.81%
Payout Ratio 268.80%
Expected Next Dividend Payment Aug 2025
Ex Date Announcement Date Payment Date Details
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Cash
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Cash
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Cash
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Cash
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 3.28 2 1.72
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria